MNOV
MEDICINOVA INC
NASDAQ · Healthcare · Biotechnology · US
$1.42
+0.00%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.41
From 52W high−58.84%
Volume137740.00
Market cap$69.89M
P/E (TTM)—
P/S (TTM)75.9x
Div yield—
Key dataOct 19, 2026
Open
$1.41
From 52W high
−58.84%
Volume
137740.00
Market cap
$69.89M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.1x
P/E (TTM)
—
RSI (14)
35.7
MomentumView details →
1D Return
+0.00%
YTD Return
+8.02%
SummaryUpdated Jun 1, 2026
MediciNova, Inc. (NASDAQ:MNOV) is a biopharmaceutical company founded in 2000 and headquartered in La Jolla, California. The company went public in December 2006 and focuses on developing novel small molecule therapeutics for serious diseases with significant unmet medical needs. MediciNova operates as a clinical-stage biotechnology company with no marketed products, relying on its pipeline of drug candidates in various stages of development across multiple therapeutic areas including neurology, respiratory diseases, and oncology.
Similar companies
Latest newsMore news →
At 09:03 on September 30, Accel HD led special sell-side quotes with 1.49 billion yen in sell orders versus 100 million yen in buy orders, while WTI crude, F-Force G and Rentrax also saw sell quotes lowered.20d agoMediciNova announced topline results of a Phase 2 clinical trial of MN-001 for hypertriglyceridemia and fatty liver disease associated with type 2 diabetes, where mean reductions in serum triglycerides and liver fat exceeded placebo but were not statistically significant.21d agoOn September 29, 2026, Hyugapla (7133) led special buy quotes with 6.09 billion yen in buy orders and zero sell orders, while Nidec (6594) led special sell quotes with 5.42 billion yen in sell orders against 3.15 billion yen in buy orders on the Tokyo market.21d ago